The potential therapeutic targets for ASO and siRNA include genes involved in adipocyte differentiation, lipid metabolism, insulin sensitivity and inflammatory processes, as well as those linked to specific mutations in lipodystrophy-associated genes. This evidence concerns the gene INS and lipodystrophy.